Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Malignant hematopoietic cells of myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemias (CMML) and acute myeloid leukemias (AML) may be vulnerable to inhibition of poly(ADP ribose) polymerase 1/2 (PARP1/2) and apurinic/apyrimidinic endonuclease 1 (APE1). PARP1/2 and APE1 are critical enzym...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Kohl, Vanessa, Flach, Johanna, Naumann, Nicole, Brendel, Susanne, Kleiner, Helga, Weiss, Christel, Seifarth, Wolfgang, Nowak, Daniel, Hofmann, Wolf-Karsten, Fabarius, Alice, Popp, Henning D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6826540/
https://ncbi.nlm.nih.gov/pubmed/31623402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101493
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi